Skip to the content
 
  • Payment Plans
  • Login for Professionals
  • English
    • Deutsch
    • Français
    • Italiano
    • English
  • Healthy Travelling
  • Countries
  • News
  • Special travellers
  • Health risks
  • Vaccinations
  • Ask a specialist

MENU

  • LogIn
  • English
    • Deutsch
    • Français
    • Italiano
    • English
  • Healthy Travelling
  • Countries
  • News
  • Special travellers
  • Health risks
  • Vaccinations
  • Ask a specialist
 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

At the 44th meeting on 14 January 2025, the Emergency Committee under the International Health Regulations (IHR) reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the global targets to interrupt endemic WPV1 transmission in 2026 and to stop cVDPV2 outbreaks by 2028 with subsequent certification of WPV1 eradication and cVDPV2 elimination. Technical updates were received about the situation in the following countries: Afghanistan, Angola, Germany, Lao People’s Democratic Republic, Namibia, Pakistan and Papua New Guinea.

 

Wild poliovirus (WPV):

  • Since 1 October 2025, 9 new WPV1 cases have been reported from the two endemic countries, Afghanistan (5) and Pakistan (4).
  • Cumulatively in 2025:
    • 40 WPV1 cases in Afghanistan (9), Pakistan (31).
    • WPV1 positive environmental samples sites: Afghanistan (64), Pakistan (608), Germany (1).
    • Germany: On 10 November 2025, the GPEI confirmed the detection of wild poliovirus type 1 (WPV1) in an environmental sample collected through routine surveillance in Hamburg, Germany, on 7 October 2025. Genetic sequencing indicates that this WPV1 detection is linked to WPV1 previously identified in Kandahar, Afghanistan, in August 2025, suggesting a recent importation into Germany. An environmental sample collected from the same site on 13 October 2025 also showed the presence of WPV1. No further WPV1 detections have been reported in subsequent environmental samples collected after 13 October 2025. 

 

Circulating vaccine derived poliovirus (cVDPV):

  • In 2025, a total of 192 cVDPV2 cases, 7 cVDPV3 cases, 3 cVDPV1 cases were reported.
  • Since the last Emergency Committee meeting in October 2025:
    • New cVDPV1 outbreaks in Laos. In Algeria, Djibouti, DRC, and Israel, outbreaks are ongoing.
    • New cVDPV2 outbreaks are in Namibia, with ongoing outbreaks in 25 additional countries (see below).
    • cVDPV3 outbreaks in Cameroon, Chad, and Guinea are ongoing.

 

The Committee unanimously concluded that the risk of international spread of poliovirus continues to constitute a Public Health Emergency of International Concern (PHEIC) and recommended extending the Temporary Recommendations for a further three months.

 

The Committee, after a thorough review of the epidemiological and programmatic situation, unanimously concluded that the event does not constitute a pandemic emergency.

 

Risk categories and advice aimed at reducing the risk of international spread of WPV1 and cVDPVs:

  1. States infected with WPV1, cVDPV1 or cVDPV3.
  2. States infected with cVDPV2, with or without evidence of local transmission.
  3. States previously infected by WPV1 or cVDPV within the last 24 months (last detection >13 months).
Updates of WHO temporary poliovirus vaccination recommendation and ECTM recommendations by country can be found at the respective country pages at healthytravel.ch. 
WHO statement 04.03.2026

Chikungunya virus transmission is again increasing in Mayotte. Since 1 January 2026, more than 270 autochthonous confirmed cases have been reported, with an average of about 65 cases per week during the last two weeks of February.

 

Mayotte also experienced a chikungunya outbreak in 2025, with 1’270 confirmed cases and a peak of 232 cases in epidemiological week 21. The total number of cases was likely underestimated due to limited access to healthcare.

mayotte.png

Elevated chikungunya transmission should be considered.

 

Optimal mosquito protection 24/7, also in cities, this also protects you against other mosquito-borne diseases. Vaccination against chikungunya is not licensed in Switzerland.

 

For vaccination recommendations, see ECTM statement. 

 

In case of fever:

  • Get tested to rule out malaria
  • Ensure adequate hydration and apply paracetamol products.
ECDC, 5.3.2026 | ARS France, 27.2.2026

Get in touch with us

  • Sekretariat Schweizerische Fachgesellschaft für Tropen- und Reisemedizin,
    Socinstrasse 55, Postfach, 4002 Basel

  • info@healthytravel.ch
  • Ask a specialist
  • News
  • Contact
  • Payment Plans
  • Sponsors
  • Legal notice

Copyright © 2026. All Rights Reserved

0

Bookmarks